Understanding the New USP Chapter 1224 for Transfer of Analytical Methods

Training Options

  •   Duration: 75 Minutes  
  • Recorded Access recorded version only for one participant; unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)
    Price: $295.00
  • Refund Policy

Overview:

When validated methods are transferred between laboratories and sites, their validated state should be maintained to ensure the same reliable results in the receiving laboratory.

So far there has not been an official guidance on what exactly is expected to maintain 'the validated state'. Now the USP has published a proposal for a general chapter <1224>. Also the FDA has released an official guidance on how to conduct and document method transfer. The new USP chapter will become official with USP 35. Now it is a good time to learn how to conduct and document method transfer. This seminar will give a good understanding of USP and FDA requirement and provide recommendations and tools for effective implementation.

Reference Material:

For easy implementation, attendees will receive
  • SOP: Transfer of Analytical Methods
  • Checklist: Transfer of Analytical Methods and Procedures
  • Master Plan template and examples: - Transfer of Analytical Methods and procedures
Areas Covered in the Session:
  • FDA and International expectations for method transfer
  • Examples of FDA warning letters and how to avoid them
  • The FDA Guidance on method transfer.
  • The proposal for a new USP chapter <1224>: history, status, future
  • Four approaches for analytical method transfer and testing
  • Responsibilities of the transferring and receiving laboratory
  • Developing a transfer plan and a pre-approval protocol
  • Conducting comparative studies
  • Criteria and approaches for risk based testing: what, when, how much?
  • The importance and selection of acceptance criteria
  • Dealing with technology transfer: validation requirements, regulatory notification.
  • Method transfer from standard HPLC to UHPLC
  • Most likely failures during method transfer
  • Handling deviations from documented acceptance criteria
  • Criteria for transfer waiver (omission of formal transfer)
Who Will Benefit:
  • Analysts
  • Lab Supervisors and Managers
  • QA managers and personnel
  • Analysts
  • Consultants
  • Teachers
Ludwig Huber, Ph.D., is Director of Labcompliance and Chief Advisor for global FDA compliance at Agilent Technologies. He is the editor of Labcompliance, the global on-line resource for validation and compliance issues for laboratories. He is the author of the books "Validation and Qualification in Analytical Laboratories, and "Validation of Computerized Analytical and Networked Systems", Informa Healthcare.


Related Webinars:

No Related Webinars Available

Copyright © 2014 GlobalCompliancePanel. All rights reserved. Netzealous
Back to Top